Syncom Formulations (India) Limited Stock Price Today (NSE: SYNCOMF)
Fundamental Score
Syncom Formulations (India) Limited Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Syncom Formulations (India) Limited share price today is ₹18.41, down 0.65% on NSE/BSE as of 16 September 2026. Syncom Formulations (India) Limited (SYNCOMF) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹1.73K (Cr). The 52-week high for SYNCOMF share price is ₹22.59 and the 52-week low is ₹10.21. At a P/E ratio of 19.59x, SYNCOMF is currently trading below its industry average P/E of 34.89x. 0
Syncom Formulations (India) Limited Share Price Chart — NSE/BSE Historical Performance
Syncom Formulations (India) Limited share price chart: 34.31% return over the past month. 52-week high ₹22.59, 52-week low ₹10.21.
Syncom Formulations (India) Limited — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹18.56 | ₹18.88 | ₹16.61 | ₹18.41 | 105.24L (Cr) | |
| ₹19.69 | ₹19.85 | ₹18.44 | ₹18.53 | 53.70L (Cr) | |
| ₹18.98 | ₹20.10 | ₹18.51 | ₹19.46 | 91.48L (Cr) | |
| ₹20.25 | ₹20.28 | ₹19.06 | ₹19.26 | 84.04L (Cr) | |
| ₹21.17 | ₹21.32 | ₹20.05 | ₹20.14 | 63.47L (Cr) | |
| ₹20.40 | ₹21.50 | ₹20.40 | ₹20.97 | 124.68L (Cr) | |
| ₹20.08 | ₹20.57 | ₹19.73 | ₹20.27 | 112.96L (Cr) | |
| ₹20.93 | ₹21.88 | ₹20.01 | ₹20.58 | 167.88L (Cr) | |
| ₹21.43 | ₹22.59 | ₹20.66 | ₹21.36 | 248.72L (Cr) | |
| ₹20.07 | ₹21.65 | ₹19.64 | ₹21.39 | 289.86L (Cr) |
Syncom Formulations (India) Limited — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹19.50 | ₹22.59 | ₹16.61 | ₹18.41 | -5.59% | |
| ₹13.30 | ₹20.38 | ₹12.87 | ₹19.49 | +46.54% | |
| ₹14.35 | ₹14.78 | ₹12.86 | ₹13.12 | -8.57% | |
| ₹15.01 | ₹15.38 | ₹13.74 | ₹14.26 | -5.00% | |
| ₹13.74 | ₹16.56 | ₹13.21 | ₹15.01 | +9.24% | |
| ₹10.70 | ₹14.43 | ₹10.47 | ₹13.74 | +28.41% | |
| ₹11.62 | ₹12.60 | ₹10.21 | ₹10.30 | -11.36% | |
| ₹13.90 | ₹14.83 | ₹11.53 | ₹12.79 | -7.99% | |
| ₹14.26 | ₹14.70 | ₹11.65 | ₹12.96 | -9.12% | |
| ₹15.60 | ₹15.85 | ₹14.02 | ₹14.26 | -8.59% | |
| ₹16.37 | ₹17.25 | ₹15.35 | ₹15.63 | -4.52% | |
| ₹16.14 | ₹17.40 | ₹16.00 | ₹16.44 | +1.86% |
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Syncom Formulations (India) Limited Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Syncom Formulations (India) Limited Fundamental Analysis & Valuation Benchmarking
Educational evaluation of SYNCOMF across key market metrics for learning purposes.
Positive Indicators
11 factors identified
Excellent ROCE Performance (26.09%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Attractive Valuation (P/E: 19.59 vs Industry: 34.89)
Observation: Trading at discount to industry peers.
Analysis: P/E below industry average may present value opportunity.
Consistent Growth Track Record (14.73% CAGR)
Observation: Strong 5-year sales compound annual growth rate.
Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model.
Excellent EPS Growth (17.04% CAGR)
Observation: Outstanding 5-year earnings per share compound growth.
Analysis: EPS CAGR >15% indicates strong wealth creation potential.
Strong Profit Growth Track Record (21.19% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model.
Conservative Debt Levels (D/E: 0.00)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (88.55x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Healthy Liquidity Position (Current Ratio: 4.55)
Observation: Strong short-term liquidity to meet obligations.
Analysis: Current ratio >1.5 indicates good working capital management.
Strong Cash Generation (₹40.70 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Balanced Promoter Holding (50.57%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
5 factors identified
Below-Average Return on Equity (0.00%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
High Price-to-Book Ratio (5.06x)
Observation: Trading at significant premium to book value.
Analysis: High P/B ratios may indicate overvaluation relative to asset base.
Profit Decline Concern (-100.00%)
Observation: Significant year-over-year profit contraction observed.
Analysis: Declining profitability requires investigation into underlying causes.
Limited Institutional Interest (FII+DII: 0.21%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Syncom Formulations (India) Limited vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Syncom Formulations (India) Limited with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Syncom Formulations (India) LimitedSyncom Formulat...Selected✓ SYNCOMF • 524470 | 71/100 | ₹18.41₹18 | ₹1730.54₹1730.54 | 19.59Average 19.6 Average | 0.00%Poor 0.00% Poor | 26.09%Excellent 26.09% Excellent | 0.00Excellent 0.0 Excellent | 21.19%Excellent 21.19% Excellent | 14.73%Good 14.73% Good | 0.00% |
Sun Pharmaceutical Industries LimitedSun Pharmaceuti... SUNPHARMA • 524715 | 66.4/100 | ₹1861.00₹1861 | ₹446509.73₹446509.73 | 36.92Average 36.9 Average | 14.74%Average 14.74% Average | 19.31%Good 19.31% Good | 0.05Excellent 0.0 Excellent | 31.64%Excellent 31.64% Excellent | 11.78%Good 11.78% Good | 0.82% |
Divi's Laboratories LimitedDivi's Laborato... DIVISLAB • 532488 | 56.3/100 | ₹9438.50₹9439 | ₹250120.25₹250120.25 | 85.64Average 85.6 Average | 16.19%Good 16.19% Good | 20.38%Excellent 20.38% Excellent | 0.00Excellent 0.0 Excellent | 5.29%Good 5.29% Good | 8.67%Good 8.67% Good | 0.41% |
Torrent Pharmaceuticals LimitedTorrent Pharmac... TORNTPHARM • 500420 | 51.4/100 | ₹4930.00₹4930 | ₹166860.78₹166860.78 | 78.75Average 78.8 Average | 27.07%Excellent 27.07% Excellent | 14.09%Average 14.09% Average | 1.76Average 1.8 Average | 11.56%Good 11.56% Good | 11.80%Good 11.80% Good | 0.76% |
Zydus Lifesciences LimitedZydus Lifescien... ZYDUSLIFE • 532321 | 74.1/100 | ₹1117.80₹1118 | ₹111556.44₹111556.44 | 24.91Average 24.9 Average | 19.74%Good 19.74% Good | 21.77%Excellent 21.77% Excellent | 0.43Excellent 0.4 Excellent | 18.76%Excellent 18.76% Excellent | 12.45%Good 12.45% Good | 0.09% |
Cipla LimitedCipla Limited... CIPLA • 500087 | 40.2/100 | ₹1373.30₹1373 | ₹110942.04₹110942.04 | 32.90Average 32.9 Average | 11.82%Average 11.82% Average | 15.67%Good 15.67% Good | 0.01Excellent 0.0 Excellent | 10.03%Good 10.03% Good | 8.01%Good 8.01% Good | 0.90% |
Laurus Labs LimitedLaurus Labs Lim... LAURUSLABS • 540222 | 34.1/100 | ₹1945.00₹1945 | ₹105078.63₹105078.63 | 96.00Average 96.0 Average | 18.19%Good 18.19% Good | 21.35%Excellent 21.35% Excellent | 0.45Excellent 0.5 Excellent | -1.89%Poor -1.89% Poor | 7.19%Good 7.19% Good | 0.13% |
Aurobindo Pharma LimitedAurobindo Pharm... AUROPHARMA • 524804 | 24.6/100 | ₹1668.40₹1668 | ₹95999.74₹95999.74 | 26.07Average 26.1 Average | 9.94%Poor 9.94% Poor | 14.54%Average 14.54% Average | 0.20Excellent 0.2 Excellent | -8.07%Poor -8.07% Poor | 6.32%Good 6.32% Good | 0.26% |
Dr. Reddy's Laboratories LimitedDr. Reddy's Lab... DRREDDY • 500124 | 41/100 | ₹1143.00₹1143 | ₹95440.50₹95440.50 | 29.54Average 29.5 Average | 11.75%Average 11.75% Average | 14.80%Average 14.80% Average | 0.17Excellent 0.2 Excellent | 16.54%Excellent 16.54% Excellent | 12.09%Good 12.09% Good | 0.65% |
Lupin LimitedLupin Limited... LUPIN • 500257 | 83.4/100 | ₹2077.80₹2078 | ₹95007.40₹95007.40 | 17.17Average 17.2 Average | 26.90%Excellent 26.90% Excellent | 31.80%Excellent 31.80% Excellent | 0.26Excellent 0.3 Excellent | 34.39%Excellent 34.39% Excellent | 13.02%Good 13.02% Good | 0.72% |
Mankind Pharma LimitedMankind Pharma ... MANKIND • 543904 | 61.5/100 | ₹2238.40₹2238 | ₹92445.92₹92445.92 | 45.23Average 45.2 Average | 12.49%Average 12.49% Average | 13.56%Average 13.56% Average | 0.39Excellent 0.4 Excellent | 10.52%Good 10.52% Good | 18.10%Excellent 18.10% Excellent | 0.04% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Limited share price446509.73 Cr
- Divi's Laboratories Limited share price250120.25 Cr
- Torrent Pharmaceuticals Limited share price166860.78 Cr
- Zydus Lifesciences Limited share price111556.44 Cr
- Cipla Limited share price110942.04 Cr
Syncom Formulations (India) Limited PE Ratio History
Historical price-to-earnings ratio for SYNCOMF — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2025 | ₹0.57 | ₹14.26 | 25x |
| FY 2024 | ₹0.34 | ₹20.00 | 58.8x |
| FY 2023 | ₹0.22 | ₹15.05 | 69.6x |
| FY 2022 | ₹0.24 | ₹8.85 | 36.9x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Syncom Formulations (India) Limited Dividend History
Annual cash dividends paid by SYNCOMF — dividend yield N/A
| Financial Year | Dividends Paid (₹ Cr) |
|---|---|
| FY 2023 | ₹2.82 Cr |
Cash dividends from annual cash flow statements. Past dividends do not guarantee future payments. Not investment advice.
Syncom Formulations (India) Limited Quarterly Performance
Latest quarterly metrics for SYNCOMF — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
7.38%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
-100.00%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
14.73%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
21.19%
Compounded annual net profit growth over 5 years
Syncom Formulations (India) Limited Technical Indicators
SMA 50, SMA 200, RSI and volume signals for SYNCOMF — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Syncom Formulations (India) Limited Financial Statements
Annual income statement, balance sheet and cash flow for Syncom Formulations (India) Limited (SYNCOMF) — sourced from NSE/BSE filings.
Financial Results & Statements
Latest quarterly, annual and period-wise financial data for Syncom Formulations (India) Limited
About SYNCOMF (Syncom Formulations (India) Limited)
Syncom Formulations India Ltd is a dynamic pharmaceutical company forging a path in the global healthcare landscape. With a foundation built on quality and innovation, Syncom manuf...actures and distributes a diverse portfolio of pharmaceutical formulations designed to address a wide spectrum of medical needs. The company’s commitment to research and development drives the creation of effective and accessible healthcare solutions, catering to both domestic and international markets. Syncom Formulations strives to improve the well-being of individuals across the globe by providing reliable and affordable medications that adhere to stringent quality standards and regulatory requirements. The company’s operational framework encompasses several strategic business divisions, including pharmaceutical manufacturing, commodity trading, and property rentals, which contribute to a well-rounded and diversified business model. Within the pharmaceutical segment, Syncom Formulations specializes in a comprehensive array of therapeutic categories, ranging from treatments for common ailments to specialized formulations addressing specific health concerns. Their product offerings include a variety of dosage forms such as tablets, capsules, syrups, and injectables, ensuring versatility in meeting the diverse needs of patients and healthcare professionals. Syncom is dedicated to maintaining excellence in every aspect of its operations, from product development to supply chain management. Syncom Formulations is committed to delivering value to its stakeholders through sustainable growth and responsible business practices. As a forward-thinking pharmaceutical company, Syncom embraces technological advancements and innovative strategies to enhance its manufacturing processes, expand its market reach, and strengthen its competitive position. Through a focus on customer satisfaction, product quality, and ethical conduct, Syncom Formulations endeavors to build lasting relationships with its partners and contribute positively to the healthcare industry. The company aims to remain at the forefront of pharmaceutical innovation, providing reliable and impactful healthcare solutions that improve lives worldwide.
Company Details
Key Leadership
SYNCOMF Share Price: Frequently Asked Questions
What is the current share price of Syncom Formulations (India) Limited?
Syncom Formulations (India) Limited (SYNCOMF) trades at ₹18.41 on NSE and BSE. Market cap ₹1.73K (Cr). Educational data only.
What is the P/E ratio of Syncom Formulations (India) Limited?
Syncom Formulations (India) Limited has a P/E of 19.59x vs industry average 34.89x.
What is the Bull Run score for Syncom Formulations (India) Limited?
Syncom Formulations (India) Limited has a Bull Run score of 71/100 based on 25+ financial parameters.
Does Syncom Formulations (India) Limited pay dividends?
Syncom Formulations (India) Limited has a dividend yield of 0.00%. Past dividends don't guarantee future payments.
What is the ROE of Syncom Formulations (India) Limited?
Syncom Formulations (India) Limited has ROE of 0.00%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Syncom Formulations (India) Limited?
Syncom Formulations (India) Limited has debt-to-equity of 0.00.
Is Syncom Formulations (India) Limited a good investment?
Bull Run gives Syncom Formulations (India) Limited a score of 71/100. This is not investment advice — consult a SEBI-registered advisor.